Emerging avenues also involve personalized neoantigen-based vaccines aimed at activating CD8+ T cells with tumor specificity, as well as adoptive immunotherapies including infusion of TILs and chimeric antigen receptor T (CAR-T) cells approaches designed to expand and diversify the cytotoxic immune repertoire (122–124). Here, CD8A is linked to neoplasm.